From: Surface antigen expression on peripheral blood monocytes in women with gynecologic malignancies
Parameter | Endometrial Cancer (N = 42) | Cervical Cancer (N = 13) | Ovarian Cancer (N = 14) | Group I (N = 20) | Group II (N = 23) |
---|---|---|---|---|---|
SR (mm • h-1) | 20.47 ± 14.11; | 16.58 ± 16.81; | 23.58 ± 12.94; | 17.60 ± 20.24; | 7.39 ± 1.70; |
18.00 *** | 12.00 * | 21.00 *** | 9.00 | 8.00 | |
(2–59) | (2–62) | (5–40) | (2–70) | (4–10) | |
CRP (mg • L-1) | 9.63 ± 19.16; | 4.48 ± 8.68; | 60.06 ± 62.42; | 9.59 ± 18.94; | 1.63 ± 0.85; |
3.60 | 0.00 ** | 34.00 *** | 0.00 | 1.50 | |
(0.00-96.30) | (0.00-23.30) | (0.00-204.00) | (0.00-78.50) | (0.50-4.00) | |
Leukocytosis (103 • μL-1) | 7.94 ± 2.42; | 8.64 ± 2.48; | 7.16 ± 2.09; | 7.02 ± 1.76; | 6.10 ± 1.30; |
7.80 ** | 8.35 ** | 6.90 | 7.41 * | 6.30 | |
(3.80-14.40) | (5.30-13.30) | (4.20-11.40) | (4.10-11.01) | (4.50-8.50) | |
Neutrophils (%) | 57.40 ± 5.44; | 61.38 ± 9.83; | 58.21 ± 5.45; | 52.64 ± 7.49; | 57.39 ± 5.90; |
57.00 | 62.10 | 57.50 | 54.35 | 56.90 | |
(26.00-78.50) | (29.30-84.60) | (48.70-69.80) | (38.00-75.70) | (47.60-69.70) | |
Lymphocytes (%) | 31.51 ± 5.31; | 29.33 ± 9.64; | 30.66 ± 5.15; | 36.80 ± 6.92; | 32.33 ± 6.20; |
30.95 | 27.10 | 31.60 | 35.40 | 32.80 | |
(12.00-58.50) | (9.40-63.10) | (17.40-41.60) | (11.30-51.80) | (20.30-45.00) | |
Monocytes (%) | 8.12 ± 1.46; | 7.09 ± 1.35; | 7.87 ± 1.45; | 9.14 ± 1.87; | 6.46 ± 0.76; |
7.95 *** | 7.10 | 7.70 *** | 8.60 *** | 6.60 | |
(4.80-13.10) | (4.70-9.50) | (5.00-10.90) | (6.20-14.10) | (4.70-9.60) | |
NLR (no titer) | 2.00 ± 0.92; | 2.85 ± 2.19; | 2.05 ± 0.76; | 1.69 ± 1.25; | 1.91 ± 0.67; |
1.82 | 2.31 | 1.84 | 1.65 | 1.77 | |
(0.44-6.54) | (0.46-9.00) | (1.17-4.01) | (0.73-6.70) | (1.06-3.43) | |
MNM (no titer) | 3.11 ± 2.00; | 3.04 ± 2.12; | 2.44 ± 1.73; | 2.62 ± 1.79; | 1.43 ± 0.61; |
2.80 *** | 2.30 ** | 1.92 | 2.48 ** | 1.42 | |
(0.41-11.07) | (0.00-7.63) | (0.00-6.30) | (0.63-7.90) | (0.57-2.41) |